FIG A2.

Forest plot of progression-free survival at interim analysis in participants with advanced metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma. The unstratified Cox regression model with Efron's method of tie handling with treatment as a covariate was used to assess the magnitude of the treatment difference between arms. CAPOX, capecitabine and oxaliplatin; CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mFOLFOX6, fluorouracil, leucovorin, and oxaliplatin; MSI, microsatellite instability; MSI-H, microsatellite instability-high; NA, North America.